Atlas Trials

Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Clinical trial NCT04763616 · COMPLETED

Trial details

NCT number
NCT04763616
Sponsor
Won Seog Kim
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Natural Killer/T-cell LymphomaRelapsed Natural Killer/T-cell LymphomaRefractory Natural Killer/T-cell Lymphoma
Start date
2021-06-25
Primary completion
2023-04-30
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.